Pharma magnate's wealth has flatlined as Sun Pharmaceutical Industries reported a 46% drop in net profits to $72 million in a recent quarter due to merger costs linked to its $4 billion acquisition of rival Ranbaxy Laboratories. But Sun remains India's most valuable drug company (recent market cap: $30.5 billion). Shanghvi personally paid $270 million for a 23% stake in struggling wind-power firm Suzlon Energy in February, causing shares to temporarily jump.
The normally reticent tycoon recently commented that inflation was eroding India's competitive advantage.